These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11910665)

  • 21. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
    Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
    Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
    Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
    Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women.
    Cengiz B; Atabekoglu C; Cetinkaya E; Cengiz SD
    Maturitas; 2003 Dec; 46(4):301-6. PubMed ID: 14625127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
    Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
    JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
    Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
    Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
    Koh KK; Jin DK; Yang SH; Lee SK; Hwang HY; Kang MH; Kim W; Kim DS; Choi IS; Shin EK
    Circulation; 2001 Apr; 103(15):1961-6. PubMed ID: 11306524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy.
    Kalyan S; Hitchcock CL; Sirrs S; Pudek M; Prior JC
    Pharmacotherapy; 2010 May; 30(5):442-52. PubMed ID: 20411996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
    Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
    Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women.
    Koh KK; Horne MK; Csako G; Waclawiw MA; Cannon RO
    Am J Cardiol; 1999 Feb; 83(3):466-9, A10. PubMed ID: 10072247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
    Callejon DR; Franceschini SA; Montes MB; Toloi MR
    Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women.
    Sumino H; Ichikawa S; Takahashi T; Sakamoto H; Goto-Onozato K; Koya S; Kanda T; Nara M; Seki K; Murakami M; Kurabayashi M
    Maturitas; 2006 Feb; 53(3):306-14. PubMed ID: 16040211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.
    Andersen LF; Gram J; Skouby SO; Jespersen J
    Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):283-9. PubMed ID: 9988788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.